Naturally Splendid Secures Exclusive Rights to Popular Plant Protein, Meat Alternative Line

Naturally Splendid Enterprises Ltd.  (TSXV: NSP) (OTCQB: NSPDF) (FSE: 50N) ("Naturally Splendid") is pleased to announce they have signed an exclusive sales and distribution agreement for an extensive line of plant-based, meat alternative products, with one of Australia's most popular plant-based manufacturers.

Naturally Splendid has come to terms with BettaLife Global Food Solutions of Australia for the exclusive sales and distribution rights for Canada, for a wide range of plant-based, meat alternative products. The Company has also been granted sales and distribution rights to access the United States market.

In North America, Naturally Splendid will market this product line under the brand NATERA Plant Based Foods: www.naterafoods.com

Although most consumers are aware of plant-based burgers, the NATERA Plant Based Food line offers consumers far more choices than most plant-based food manufacturers in North America.

NATERA Plant Based Foods have over 20 SKU's ready to go for the North American market which will begin to be systematically rolled out over the next 6 months. The company is launching 6 of the 20 products into retail beginning Oct 2020. The NATERA Plant Based Foods retail line will include: Burgers, Schnitzel, Kiev, Sweet Chili Tenders, Nuggets, and Garlic Cheese Bites.

NATERA Plant Based Foods will offer a range of plant-based alternatives for; beef, chicken, pork, fish, and shellfish. In each category there are multiple products which in turn provides significant choice for consumers looking to include plant-based foods into their eating habits.

NATERA Plant Based Foods is currently available for food service and is preparing for their retail launch targeted for Q4, 2020.

Additionally, Naturally Splendid has confirmed adequate line processing time with the manufacturer to meet current needs into Q2 of 2021. The companies have begun discussions on building out a manufacturing facility in Canada to meet anticipated consumer demand for these market disrupting products.

Naturally Splendid CEO, Mr. J. Craig Goodwin states, "Naturally Splendid began with the idea that plant-based diets are good for people and the planet. Our initial products were hemp based, given hemp boasts such an impressive nutritional profile of protein and omegas. The acquisition of Prosnack Natural Foods afforded the opportunity to become a manufacturer of nutritious plant-based bars and bites. And more recently we entered a joint venture, Plasm Pharmaceutical, to pursue a Health Canada approved phase 2 clinical trial for the curcumin-based target drug CavaltinibTM, which incorporates a patented extraction technology. In essence, a plant-based medicine. And now, with our launch of NATERA Plant Based Foods, the Company is positioned to distribute delicious plant-based meals to a wide range of consumers in this rapidly growing category. Throughout these diverse opportunities, plant-based products have remained central to our strategy as they will moving forward."

About Naturally Splendid Enterprises Ltd.

NSE operates a Safe Quality Food Level 2 certified food manufacturing facility just outside Vancouver, BC in Canada. We have established numerous healthy, functional foods under recognized brands such as Natera Sport (TM), Natera Hemp Foods (TM), CHII (TM), Elevate Me (TM) and Woods Wild Bar (TM). The Company has a myriad of new products and line extensions under development that are approaching launch. NSE has also developed proprietary technologies for the extraction of high demand, healthy omega 3 and 6 oils from hemp. NSE is the current "go-to" manufacturer for healthy, functional food products and ingredients focusing on plant-based ingredients. The Company provides contract manufacturing services for many global healthy food companies, private labelling a wide variety of nutritional food products destined for global healthy food markets.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors

Mr. J. Craig Goodwin
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP - TSX Venture; NSPDF - OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office: (604) 465-0548
Fax: (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid's control including, Naturally Splendid's ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64931

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less

Latest Press Releases

Related News

×